In case you missed the live webinar, or you would like to watch it again, here is the link to the replay video: https://event.webinarjam.com/go/replay/516/kr4vrblmb8xix5t1  

To earn a CPD point from watching the replay, email john.woodford@newmedia.co.za to let him know that you have watched the webinar. 

The key points from this presentation are: 

Currently, the only two-drug option as treatment initiation is 3TC (or FTC) + DTG.​ 

This is non-inferior to three-drug regimens at least to three years. There is a similar safety profile and a small renal advantage.​ 

BUT, have to be careful in who you select for this regimen:​ 

• Viral load must be <500,000 copies/mL.​ 
• CD4 must be <200 cells/mm3.​ 
• Can’t have hepatitis B or TB.​ 
• Must be a true initiation (not re-initiation).​ 
• Should ideally be a patient who you don’t have adherence concerns about.​ 

Patients on other first line therapies who are virally suppressed and have never had any virological failure could be shifted to:​ 

• 3TC + DTG or ​ 
• 3TC + RPV or ​ 
• CAB + RPV.​ 
• … if this makes sense from a cost or side-effect point of view.​ 

Be careful with: hepatitis B, TB, key drug-interactions with RPV, patient needs to be reliably adherent.​